Celcuity Q3 net loss $18.4M; raises $50M; advances gedatolisib in prostate cancer

Celcuity Inc.

2023-Q3 EPS reported -$2.05

Q3 net loss $18.4M ($0.83 loss per share) vs $10.9M ($0.75) YoY; non-GAAP adjusted loss $17.3M ($0.78).
Closed $50M private placement equity in October 2023; cash runway extended into mid-2026.
FDA cleared IND for gedatolisib + darolutamide in mCRPC; entered Bayer supply agreement for darolutamide.
VIKTORIA-1 Phase 3 (HR+/HER2- breast cancer) on track: PIK3CA wt data H2 2024, PIK3CA mut data H1 2025.
CELC-G-201 Phase 1b/2 (mCRPC) site activation Q1 2024; initial data expected H1 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Celcuity Inc. reported the third quarter ended September 30, 2023 results: net income $18.4 million, EPS $0.83 loss per share.

Period: the third quarter ended September 30, 2023
Net income: $18.4 million
EPS: $0.83 loss per share
Result: reported results

Exact text from the filing

Net loss for the third quarter of 2023 was $18.4 million, or $0.83 loss per share, compared to a net loss of $10.9 million, or $0.75 loss per share, for the third quarter of 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Celcuity Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-040317

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.